Alterity Therapeutics Files 6-K, Incorporates Securities Application
Ticker: PRNAF · Form: 6-K · Filed: Apr 15, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, securities-application
Related Tickers: ATH
TL;DR
ALTERITY THERAPEUTICS (ATH) files 6-K, includes securities application for ATH. Procedural filing.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on April 15, 2024, to incorporate by reference into several of its existing SEC registration statements. This filing includes an application for quotation of securities, identified as exhibit 99.1, related to ATH.
Why It Matters
This filing is procedural, incorporating previous documents into active registration statements, which is necessary for ongoing compliance and potential future offerings.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously submitted documents into existing registration statements, with no new material financial or operational information disclosed.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH (company) — Securities identifier
- April 15, 2024 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being incorporated by reference into Alterity Therapeutics Limited's existing Registration Statements on Form S-8 and Form F-3.
What specific exhibit is included with this filing?
Exhibit 99.1, an Application for quotation of securities - ATH, is submitted with this Form 6-K.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is April 15, 2024.
Which SEC registration statements is this 6-K being incorporated into?
This 6-K is being incorporated into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-04-15 08:00:21
Filing Documents
- ea0203887-6k_alterity.htm (6-K) — 14KB
- ea020388701ex99-1_alterity.htm (EX-99.1) — 37KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- ex99-1_002.jpg (GRAPHIC) — 1KB
- ex99-1_003.jpg (GRAPHIC) — 1KB
- ex99-1_004.jpg (GRAPHIC) — 1KB
- 0001213900-24-032741.txt ( ) — 57KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Application for quotation of securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: April 15 , 2024 2